<DOC>
	<DOCNO>NCT01724294</DOCNO>
	<brief_summary>This multicenter , observational study evaluate correlation clinical biological factor International Prognostic Index ( IPI ) prognostic factor patient diffuse large B-cell lymphoma receive first-line treatment MabThera/Rituxan ( rituximab ) combination CHOP chemotherapy . Eligible patient receive treatment accord standard care local guideline follow duration treatment ( approximately 8 month ) 1 year follow-up .</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Combination With CHOP Chemotherapy First-Line Patients With Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Adult patient , &gt; 18 year age Patients diagnose diffuse large Bcell lymphoma firstline treatment RCHOP Prior chemotherapy treatment diffuse large Bcell lymphoma Contraindications exclusion criterion accord Summary Product Characteristics MabThera/Rituxan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>